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Objectives: To build an Excel calculator, including demographic and clinical char-
acteristics of Ankylosing Spondylitis (AS) patients, and estimate annual health 
care costs of AS patients in Turkey. MethOds: The study data was obtained from 
the Turkish national health insurance database, MEDULA (2009-2011). Adult AS 
patients (ages 18-99) were identified for the identification period (June 1, 2010 - 
December 31, 2010) through the use of International Classification of Disease Tenth 
Revision Clinical Modification (ICD-10-CM) codes. Patients were required to have 
two AS diagnoses at least 60 days apart, with at least 1 year of continuous health 
plan enrollment for the baseline and follow-up years. Patients were grouped as 
prevalent and incident cases, and generalized linear models (GLMs) were used to 
estimate risk-adjusted total annual costs for prevalent and incident cases. The 
expected annual cost value was based on patient demographic and clinical char-
acteristics. Coefficients of patients’ demographic and clinical characteristics were 
built in the Excel calculator. Using the calculation, a marginal effects table was 
created after GLM estimation. Results: A total of 2986 patients met all inclusion 
criteria (603 incident; 2383 prevalent patients). Demographic and clinical char-
acteristics of the patients were entered into the Excel calculator. Risk-adjusted 
annual total costs were calculated as € 3307 for prevalent cases and € 2000 for 
incident cases. Prior biologic use significantly contributed to total medical costs 
for both prevalent and incident AS patients (p< 0.001). For incidence cases, the cost 
of care was lower for the 18-39 age group when controlling for other factors. For 
prevalent cases, there were no differences in health care costs in terms of region, 
gender, age, comorbidities, or prior non-steroidal anti-inflammatory drug (NSAID) 
or disease-modifying anti-rheumatic drug (DMARD) use. cOnclusiOns: An Excel 
calculator is an important tool to estimate and compare AS-related health care 
costs in outcomes research.
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Objectives: To derive a claims-based severity index for rheumatoid arthritis 
(SIFRA) and examine its impact on prevalent rheumatoid arthritis (RA) patients in 
Turkey. MethOds: Using the Turkish national health insurance database MEDULA 
(01JUN2009-31DEC2011), prevalent RA patients were identified. Patients were 
required to be age 18-99, have two RA diagnoses ≥ 60 days apart and be continu-
ously enrolled 1 year pre- (baseline period) and post-index date (follow-up), which 
was the first RA claim during the identification period (01JUN2010-31DEC2010). The 
SIFRA score was derived for each patient. RA-related indicators were sub-grouped as 
clinical and functional status, extra-articular manifestations, surgical history and 
medications. The strength of each relationship was measured from 0= no relation-
ship to 6= perfect relationship, and assessed by six board-certified, clinically active 
rheumatologists according to the Delphi panel method. The index was previously 
validated and applied to the U.S. Department of Veteran Affairs, Veterans Health 
Administration (VHA) data. Results: For the total of 1,920 identified RA patients, 
SIFRA scores ranged between 0 and 69.40, with a mean value of 14.21, and a standard 
deviation (SD) of 10.26. Mean SIFRA scores were 7.05 (49.57%), which consisted of 
clinical and functional status variables, followed by 6.32 (44.47%) for medications, 
0.48 (3.40%) for radiology and laboratory findings, 0.32 (2.25%) for extra-articular 
manifestations (pulmonary nodules, subcutaneous nodules, vasculitis ever, Felty’s 
syndrome ever), and 0.04 (0.31%) for surgical history (cervical spine fusion, hand/
foot joint replacement, foot joint/ankle/wrist fusion, total hip/knee/elbow/shoulder 
replacement). cOnclusiOns: SIFRA demonstrated evidence of being a significant 
determinant for health care costs and biologic therapy use. This study suggests 
that SIFRA could be an important methodological tool to control for severity in 
RA-related outcomes research. Any comparative effectiveness studies in RA treat-
ment should include severity scores in the analysis.
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Objectives: Clinical oncology research projects require participation of oncolo-
gists and/or hematologists to recruit patients and/or assess clinical outcomes. A 
variety of methods is used to recruit office or hospital based physicans. Specifically 
for studies with an epidemiological aspect, the study should not rely on the typi-
cal clinical expert sites, thus, alternative recruitment pathways are increasingly 
considered. The objective of our study was thus to assess the benefits of using 
physician panels for site recruitment. MethOds: In 2012, a representative survey 
among members of a managed physician panel (All Global’s managed panel of 
oncologists and hematologists in US, UK, GER, FR, IT and SP) was conducted. A 
Sample of oncologists and hematologists was selected. The panel was stratified by 
country and within the strata physicians were randomly selected. 335 out of 1.303 
oncologists and hematologists in the sample (25,7%) reported about their former 
experience with clinical trials and post-approval studies, their willingness to par-
ticipate in future studies and their adherence to aspects of GCP rules. Results: A 
total of 284 (84,7%) of the physicians have formerly participated in clinical trials and 
276 (67,2%) in post-approval studies. A total of 88,9% of the experienced oncologists 
and hematologists were willing to participate in future studies. More than 80% of 
this group was ready to be named as principal investigator to an ethical commit-
tee, to report serious adverse events to the sponsor of the study and to ask patients 
for written informed consent. No substantial difference between countries was 
detected. cOnclusiOns: Since no special incentive was offered for participation 
the response rate was satisfactory Managed oncologist panels are a cost-effective, 
odds model has a natural interpretation of the treatment effect, is flexible in terms of 
handling data with different numbers of categories, but relies on the proportional odds 
assumption. The ordered logistic model also has a natural interpretation of the treat-
ment effect, but increases in complexity when handling data with a large number of 
categories. The multinomial model’s interpretation for the treatment effect is difficult, 
but it can model a large number of categories and can handle unordered competing 
risks and time dependent data. cOnclusiOns: There are three methods for incor-
porating multinomial data in a meta-analysis framework with various advantages 
and disadvantages. Selection of the appropriate model appears to be most dependent 
on the characteristics of the dataset. We determine that there is sufficient cause for 
future research focusing on a quantitative comparison of these different methods.
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Objectives: While multiple treatment comparisons (MTC) generally provide strong 
evidence, many are accompanied with uncertainty that makes life challenging for 
decison makers. Seeking reduction in uncertainty from non-comparative trial can ease 
decision-making, but the validity of this approach must be tested. Using an example of 
treatments for cryptococcal meningitis (CM), our objective was to assess the value and 
validity of incorporating non-comparative trial evidence via prior distributions in the 
Bayesian MTC framework. MethOds: We conducted a Bayesian MTC meta-analysis 
with and without informative priors and reported odds ratios (OR) with 95% credible 
intervals (CrI). Non-comparative data were incorporated in a two-stage approach. First 
meta-analysis for proportions was used to pool all relevant non-comparative outcomes 
for each treatment. Second, these results were used to construct informative priors for 
the comparative treatment effect parameters (the log odds ratios) in the Bayesian MTC. 
Treatments considered were amphotericin (AmB)-based therapy coupled with either 
flucytosine (5FC) or fluconazole (Azole). Results: Twenty-seven studies (N= 1,938), 15 
head-to-head drug comparison trials and 12 studies evaluating a single drug, described 
early mortality. Twenty-nine studies, 17 head-to-head and 12 single-arm studies, 
described late mortality. Incorporating non-comparative trials via informative priors 
improved the precision of several comparisons. For early mortality for example, the 
OR for AmB+Azole vs AmB+5FC was 0.26 (95%CrI 0.04-1.26) with a conventional MTC, 
and 0.24 (0.04-0.98) with informative priors. Use of informative priors reduced the DIC 
by 38% and the heterogeneity by 28%, indicating a better model fit. Moreover, evidence 
from the non-comparative studies was coherent with the randomized evidence, add-
ing to the validity of the approach. cOnclusiOns: Incorporating non-comparative 
studies as informative priors in Bayesian MTCs appears a viable approach for reducing 
the uncertainty in MTCs, and thus easing decision making.
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Objectives: Understanding the impact of caring for a person with schizophrenia 
on caregivers’ lives and emotional and physical well-being is of increasing interest 
for health care decison makers. The Zarit Burden Interview (ZBI) is an established 
measure of caregiver impact for Alzheimer’s disease. Face and content validity 
of the ZBI have not yet been established in schizophrenia and were explored in 
this study based on qualitative insights from caregivers of people with schizo-
phrenia. MethOds: A targeted literature review and consideration of best practice 
guidelines for development of self-report questionnaires informed initial ZBI modi-
fications. Face and content validity of the newly labelled Schizophrenia Caregiver 
Questionnaire (SCQ) were assessed via comprehensive semi-structured interviews 
with a diverse range of 19 US caregivers of people with schizophrenia. Interviews 
were initially open-ended and explored caregivers’ experience of caring for a per-
son with schizophrenia (concept elicitation). Cognitive debriefing of the draft SCQ 
then assessed relevance and understanding. Results: Initial review of the ZBI 
informed changes to item wording, recall period, and response scales to improve 
face validity. The qualitative literature review and concept elicitation interviews 
informed ten additional items assessing concepts important to caregivers, not 
included in the ZBI: tiredness, stress, disturbed sleep, sadness, medication admin-
istration issues, worries about future episodes, worsening symptoms, frustration, 
emotional highs and lows, and impact on work. Following cognitive debriefing inter-
views, five items were modified to improve relevance and understanding; otherwise, 
caregiver feedback supported the content validity and comprehensiveness of the 
resulting SCQ. cOnclusiOns: SCQ demonstrated good face and content validity 
for the assessment of caregiver impact in schizophrenia and is a promising tool for 
communication of caregiver outcomes to health care decision makers. Tiredness, 
disturbed sleep and sadness are included in depression scales hence there may be 
overlap if depression is assessed). Further work determining final SCQ content/
scoring and psychometric properties is ongoing.
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graft required for transplantation to remain cost saving compared to dialysis; the 
number of future transplants or improvement in graft survival required to avoid the 
transplant waiting list increasing. The study utilises UK costs and future costs and 
benefits were discounted at 3.5% Results: Over a 10-year projected time horizon 
the total per-patient cost saving associated with remaining on dialysis compared 
to transplant was £276,330; however, a cost saving was conditional upon achieving 
at least 3-years of functioning graft. In order to maintain the transplant waiting list 
at approximately 7,000, the number of annual transplants conducted would need to 
increase from 2,645 in 2010 to 3,640 by 2022 (a 37.6 % increase). At current activity 
levels the transplant waiting list is projected to increase by approximately 1,983; 
improvement in graft survival could potentially reduce this by 941. cOnclusiOns: 
For kidney transplantation to be cost saving recipients must maintain at least 3 
years of functioning graft. As early graft failure also impacts on future transplant 
waiting time, management strategies that maximize graft survival will reduce costs 
and improve service delivery targets.
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Objectives: Economic evaluations require patient-level resource-use to estimate 
patient costs. The National Programme for IT (2002) prompted UK health and 
social care to record patient-level resource-use using Electronic Administration 
Records (EAR’s). Retrieving EAR’s is labour intensive, but may provide better infor-
mation than self-report methods, such as the Client Service Receipt Inventory 
(CSRI), particularly in cognitively impaired people. Study objectives are to examine 
agreement, and associated cost estimates, between resource-use obtained from 
EAR's or CSRI in frail older (≥70) participants. MethOds: Health and social care 
data for 247 patients (193 cognitively impaired) were sought retrospectively six 
months post-index hospital admission. Resource-use data were collected using 
a self/proxy-reported modified CSRI, and EAR systems for primary (PC), second-
ary (SC), and social (SoC) care. Lin’s coefficient (ρc) assessed agreement between 
methods, where <0.4 = poor agreement. Results: Agreement between EAR and 
CSRI ‘per contact’ resource-use was: good, primary care (ρc = 0.60); fair, outpa-
tient care (ρc = 0.53). Agreement was incomparable for social care due to different 
resource-use recording formats; CSRI’s inpatient care question was removed due 
to the preferred detailed information available in EAR’s. EAR data provided detailed 
patient care information, such as diagnosis and procedure type, allowing improved 
allocation of unit costs. Difference in mean cost per patient between methods 
varied by service (CSRI/EAR (£): PC = 61/433; SC = 7281/7833; SoC = 252/886); CSRI 
inpatient costs were simulated assuming perfect agreement with EAR, but using 
level of information outlined within the CSRI. cOnclusiOns: EAR’s provided 
more complete patient costs. Using EAR’s reduces burden upon participants, which 
is important for frail and cognitively impaired people. Although the CSRI can be 
modified and simple to administer, poor recall and inadequate detail about patient 
care contacts prevented accurate patient-level cost estimation. Gaining access to 
EAR’s is labour intensive, but recommended in cognitively impaired participants.
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Objectives: The cost-effectiveness of pertussis vaccination has been demonstrated 
for various vaccination strategies. However, beyond financial cost expressed in mon-
etary terms vaccines also incur environmental cost expressed in CO2equivalent 
(CO2e) emission. By preventing disease, this cost might be offset by avoided events 
such as doctors’ visits, hospital bed stays, medication, amongst other items. In 
this exercise we examine the CO2e savings of a pertussis (dTpa) booster dose for 
cocooning in England and Wales. We propose a complementary measure to the 
classical Incremental Cost-Effectiveness Ratio that includes environmental cost 
instead of monetary cost. MethOds: The cradle to gate carbon footprint (from 
raw material extraction, to manufacturing, to disposal) for a typical dTpa vaccine 
dose was assessed to estimate the total amount of CO2e emitted (“carbon cost”). 
A previously published static epidemiological model was used to account for the 
reduction in incidence of pertussis. Two scenarios were compared: the current per-
tussis vaccination schedule and the same schedule with additionally a cocooning 
strategy. Results: For each dose of a dTpa vaccine manufactured, results show 
approximately 1kg of CO2e was emitted. The model shows cocooning immuniza-
tion against pertussis is projected to reduce the reported incidence of pertussis in 
young infants. Results also show that due to the reduction in emitted CO2e after 
the introduction of a cocooning strategy, vaccination is an acceptable alternative 
to the current strategy to control pertussis infection. cOnclusiOns: The method 
presented demonstrates how traditional economic models can be utilized to model 
environment features. Assessment of the cradle to gate carbon footprint of a vaccine 
provides a preliminary view of both the impact on the environmental in general 
and on the environment profile of health care in the UK.
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Objectives: In 2012, NICE initiated a multiple treatment assessment reviewing all 
licensed biologics for the treatment of rheumatoid arthritis (RA) previously treated 
experienced and high-quality source for post-approval studies. Elaborated manage-
ment processes in multi-country panels guarantee a constant quality of the panel 
over geographies.
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Objectives: Cognitive functioning is a multidimensional attribute comprising 
various domains including attention, memory, executive function, and psycho-
motor speed. The number of impacted domains and magnitude of deficits that 
equate to a classification of cognitive dysfunction (CD) are unclear. This analysis 
examined criteria used for CD classification in an observational study of depressed 
patients. MethOds: A large US health plan was used to identify depressed patients 
with a newly prescribed antidepressant. Consenting, eligible patients were inter-
viewed by telephone and completed a structured assessment of cognitive function 
measuring 4 domains: verbal episodic memory (Hopkins Verbal Learning Test-
Revised), attention (Digit Span Forward), working memory (Digit Span Backward), 
and executive function (D-KEFS-Letter Fluency Test). Patients were classified into 2 
groups based on test scores relative to normative data. “CD” was defined as patients 
with ≥ 2 scores that were ≥ 1.5 standard deviations (SD) below the normative mean 
(criterion 1) or patients with ≥ 3 scores that were ≥ 1.0 SD below the normative 
mean (criterion 2). Patients not meeting either of these were classified as “cognitive 
normal (CN).” T-tests compared differences between the groups across cognitive 
domains. Results: Of 564 eligible patients who completed the study, 45% met 
criteria for CD. Among these, 63% met both criteria for classification of CD, 19% met 
only criterion 1, and 18% met only criterion 2. The percentage of patients with scores 
≥ 1.0 SD below the mean and ≥ 1.5 SD below the mean were significantly higher in the 
CD group compared to the CN for all 4 tests. Mean scores on all domains were signifi-
cantly lower (P < 0.001) in the CD group compared to the CN group. cOnclusiOns: 
Among patients with depression, those with cognitive dysfunction had significantly 
worse functioning across all domains. This suggests that the criteria appropriately 
identified a subset of patients with impaired cognitive functioning.
ReSeaRch on MethoDS – cost Methods
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Objectives: Adequate reflection of disease progression and costs over time is 
essential in cost-effectiveness analyses (CEAs) based on health state transition mod-
els. However costing studies normally investigate the burden of metastatic breast 
cancer (MBC) without explicitly examining impact of specific disease states on 
health care costs over time. The objective of this study was to assess time-dependent 
costs of different health states of human epidermal receptor 2 (HER-2) positive 
MBC and the factors contributing to these costs. MethOds: In The Netherlands, 
HER-2 positive MBC patients were identified in three different hospitals. Resource 
use was collected during 24 months, which was linked to unit costs and related 
to time with respect to date of MBC diagnosis, disease progression and death for 
each individual patient. Subsequently, monthly costs for different health states 
were calculated. Finally, a nonlinear mixed effect modelling approach was used 
to provide a quantitative description of the time course of cumulative progression 
costs. Results: Costs during stable disease were constant over time with a mean 
of € 3,236. In contrast, monthly costs for progressive disease demonstrated a change 
over time with the largest costs in the first two months after diagnosis (p< 0.005). The 
developed mixed effect model adequately described cumulative cost time course 
and associated variability. During the last months of life, costs varied over time, with 
the last month of life as the most expensive one with a mean of € 4,522 per patient 
per month. cOnclusiOns: To reflect costs of HER-2 positive MBC accurately in 
Markov models, costs stable disease can be defined time-independent, however, 
costs of progressive disease should be defined time dependent, and costs related to 
the final months of life should be modeled as such. The mixed effect model we have 
developed could now be considered for adequate description of the time-dependent 
cost of progressive disease.
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Objectives: The UK has an ageing and growing population and the prevalence 
of renal replacement therapy (RRT) has grown by 5.0% annually since 2000. RRT 
accounts for over 2% of the current NHS expenditure. Transplantation increases 
survival, improves quality of life and maintenance costs are less than dialysis. 
Despite increasing rates of transplantation, an estimated 7,000 patients remain 
on the waiting list. The objective of this study was to quantify the relationship 
between graft survival time, total estimated cost and the number of projected 
patients on the transplant waiting list. MethOds: We utilized a population based 
simulation model with published disease progression, incidence and prevalence 
parameters specific to the UK. We evaluated the number of years of functioning 
